Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations

American Journal of Gastroenterology

Volumn 108, Issue 11, 2013, Pages 1785-1793

  Mouradov, Dmitri ^a,b   Domingo, Enric ^c   Gibbs, Peter ^a,b,d   Jorissen, Robert N ^a,b   Li, Shan ^a   Soo, Pik Ying ^a   Lipton, Lara ^a,b   Desai, Jayesh ^a   Danielsen, Havard E ^e   Oukrif, Dahmane ^e   Novelli, Marco ^f   Yau, Christopher ^g   Holmes, Christopher C ^h   Jones, Ian T ^d   McLaughlin, Stephen ⁱ   Molloy, Peter ^j   Hawkins, Nicholas J ^k   Ward, Robyn ^l   Midgely, Rachel ^h   Kerr, David ^h   Tomlinson, Ian Pm ^b   Sieber, Oliver M ^a,b,m   more..

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e UNIVERSITY OF OSLO   (Norway)

^f UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ WESTERN HOSPITAL   (Australia)

^j CSIRO   (Australia)

^k UNIVERSITY OF NEW SOUTH WALES   (Australia)

^l UNIVERSITY OF NEW SOUTH WALES   (Australia)

^m Institute of Medical Research   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PROTEIN P53; ROFECOXIB;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHROMOSOMAL INSTABILITY; CHROMOSOME 18Q; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; CHROMOSOME ABERRATIONS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; F-BOX PROTEINS; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MEMBRANE PROTEINS; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 84887231621     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.292     Document Type: Article

References (43)

1. Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997; 40: 15-24. (Pubitemid 27056393)
2. Whitehall VL, Wynter CV, Walsh MD et al. Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. Cancer Res 2002; 62: 6011-4. (Pubitemid 35244444)
3. Aaltonen LA, Salovaara R, Kristo P et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998; 338: 1481-7. (Pubitemid 28226275)
4. Alexander J, Watanabe T, Wu TT et al. Histopathological identifi cation of colon cancer with microsatellite instability. Am J Pathol 2001; 158: 527-35. (Pubitemid 32158613)
5. Duval A, Hamelin R. Genetic instability in human mismatch repair defi cient cancers. Ann Genet 2002; 45: 71-5. (Pubitemid 34823865)
6. Kambara T, Simms LA, Whitehall VL et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004; 53: 1137-44. (Pubitemid 38961968)
7. Toyota M, Ahuja N, Ohe-Toyota M et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96: 8681-6. (Pubitemid 29354851)
8. Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005; 41: 2060-70. (Pubitemid 41337947)
9. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefi t from fl uorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-57. (Pubitemid 36859476)
10. Sinicrope FA, Yang ZJ. Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer. Future Oncol 2011; 7: 467-74.
11. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643-9. (Pubitemid 29003936)
12. Miyazaki M, Furuya T, Shiraki A et al. The relationship of DNA ploidy to chromosomal instability in primary human colorectal cancers. Cancer Res 1999; 59: 5283-5. (Pubitemid 29503995)
13. Silver A, Sengupta N, Propper D et al. A distinct DNA methylation profi le associated with microsatellite and chromosomal stable sporadic colorectal cancers. Int J Cancer 2012; 130: 1082-92.
14. Sinicrope FA, Rego RL, Foster N et al. Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. Am J Gastroenterol 2006; 101: 2818-25. (Pubitemid 44902656)
15. Rowan A, Halford S, Gaasenbeek M et al. Refi ning molecular analysis in the pathways of colorectal carcinogenesis. Clin Gastroenterol Hepatol 2005; 3: 1115-23. (Pubitemid 41565378)
16. Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut 2008; 57: 941-50. (Pubitemid 351919529)
17. Domingo E, Ramamoorthy R, Oukrif D et al. Use of multivariate analysis to suggest a new molecular classifi cation of colorectal cancer. J Pathol 2013; 229: 441-8.
18. Cai G, Xu Y, Lu H et al. Clinicopathologic and molecular features of sporadic microsatellite-and chromosomal-stable colorectal cancers. Int J Colorectal Dis 2008; 23: 365-73.
19. Georgiades IB, Curtis LJ, Morris RM et al. Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability. Oncogene 1999; 18: 7933-40. (Pubitemid 30050553)
20. Hawkins NJ, Tomlinson I, Meagher A et al. Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer. Br J Cancer 2001; 84: 232-6. (Pubitemid 32113451)
21. Tang R, Wang JY, Fan CW et al. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fl uorouracil-based adjuvant therapy. Cancer Lett 2004; 210: 101-9. (Pubitemid 38692594)
22. TCGA Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-7.
23. Ren J, Li G, Ge J et al. Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum 2012; 55: 913-23.
24. Hutchins G, Southward K, Handley K et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefi ts from chemotherapy in colorectal cancer. J Clin Oncol 2011; 29: 1261-70.
25. Russo A, Bazan V, Agnese V et al. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol 2005; 16 (Suppl 4): iv44-9. (Pubitemid 43084945)
26. Roth AD, Tejpar S, Delorenzi M et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-74.
27. Ogino S, Nosho K, Kirkner GJ et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009; 27: 1477-84.
28. Ogino S, Shima K, Meyerhardt JA et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 2012; 18: 890-900.
29. Richman SD, Seymour MT, Chambers P et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefi t from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27: 5931-7.
30. Samowitz WS, Sweeney C, Herrick J et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005; 65: 6063-9.
31. Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fl uorouracil, and leucovorin as fi rst-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-9.
32. Yokota T, Ura T, Shibata N et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 2011; 104: 856-62.
33. Farina Sarasqueta A, Zeestraten EC, van Wezel T et al. PIK3CA kinase domain mutation identifi es a subgroup of stage III colon cancer patients with poor prognosis. Cell Oncol (Dordr) 2011; 34: 523-31.
34. Kato S, Iida S, Higuchi T et al. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 2007; 121: 1771-8. (Pubitemid 47417296)
35. Liao X, Morikawa T, Lochhead P et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012; 18: 2257-68.
36. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005; 92: 434-44. (Pubitemid 40395523)
37. Pendlebury S, Duchesne F, Reed KA et al. A trial of adjuvant therapy in colorectal cancer: the VICTOR trial. Clin Colorectal Cancer 2003; 3: 58-60. (Pubitemid 37220789)
38. Gill S, Sargent D. End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? Oncologist 2006; 11: 624-9. (Pubitemid 43967617)
39. Watanabe T, Kobunai T, Yamamoto Y et al. Chromosomal Instability (CIN) Phenotype, CIN High or CIN low, predicts survival for colorectal cancer. J Clin Oncol 2012; 30: 2256-64.
40. Gavin P, Colangelo LH, Fumagalli D et al. Mutation profi ling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 2012; 18: 6531-41.
41. Sinicrope FA, Rego RL, Halling KC et al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 2006; 131: 729-37. (Pubitemid 44307064)
42. Gaasenbeek M, Howarth K, Rowan AJ et al. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex changes and multiple forms of chromosomal instability in colorectal cancers. Cancer Res 2006; 66: 3471-9.
43. Birkbak NJ, Eklund AC, Li Q et al. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res 2011; 71: 3447-52.